BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.32.0//EN
X-ORIGINAL-URL:https://scandforum.ch/
X-WR-CALNAME:Scandinavian Forum Switzerland
X-WR-CALDESC:
X-WR-TIMEZONE:Europe/Zurich
BEGIN:VTIMEZONE
TZID:Europe/Zurich
X-LIC-LOCATION:Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=4SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-9bdb8b1faffa4b3d41779bb495d79fb9@scandforum.ch
DTSTART;TZID=Europe/Zurich:20260923T180000
DTEND;TZID=Europe/Zurich:20260923T210000
DTSTAMP:20260828T172508Z
CREATED:20260828
LAST-MODIFIED:20260828
PRIORITY:5
SEQUENCE:3
TRANSP:OPAQUE
SUMMARY:Small Proteins, Big Potential: New Approaches to Dementia & Cancer
DESCRIPTION:Small Proteins, Big Potential: New Approaches to Dementia & Cancer – Zurich\nHow can tiny engineered proteins help medicines reach the brain, identify tumours and act precisely where they are needed most?\nIn partnership with the Swedish Swiss Chamber of Commerce, we’re inviting you to an evening at ETH Zürich exploring how protein engineering is creating new opportunities for the diagnosis and treatment of some of today’s most challenging diseases.\n\nProfessors Stefan Ståhl and John Löfblom from KTH Royal Institute of Technology will present their research on affibodies – small, highly stable engineered proteins that are approximately 4% of the size of monoclonal antibodies. Their compact structure enables excellent tissue penetration and precise targeting.\n\nThe lecture will explore affibody-based research in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia, including technologies designed to improve transport across the blood–brain barrier. It will also examine applications in cancer imaging and targeted treatment, where affibodies can guide radioisotopes or cytotoxic agents directly to tumour cells while potentially limiting effects on healthy tissue.\n\nThe evening will be hosted at ETH Zürich by Prof. Jörg Scheuermann and Prof. Dario Neri, who will provide a short introduction to ligand discovery and ligand-based drug delivery. The scientific programme will conclude with an open discussion, followed by a networking apéritif.\n\nIntroduction Speakers\nProf. Dr. Dario Neri\nLecturer at the Department of Chemistry and Applied Biosciences, EHT Zurich\nProf. Dr. Jörg Scheuermann\nPrivatdozent am Departement Chemie und Angewandte Biowissenschaften, ETH\n\nSpeakers\nStefan Ståhl\nProfessor Molecular Biotechnology at KTH\nJohn Löfblom\nProfessor, Protein Technology at KTH\n \nFees\nSFS members: CHF 0\nNon-Members: CHF 80\n\nIn collaboration with\nSwedish Swiss Chamber of Commerce\n\n
URL:https://scandforum.ch/events/dementia-cancer_sep_23-26/
CATEGORIES:Seminar
LOCATION:Stefano-Franscini-Platz 5, 8093 Zürich
ATTACH;FMTTYPE=image/png:https://scandforum.ch/wp-content/uploads/2026/08/SFS_seminar_banner_no_logo.png
END:VEVENT
END:VCALENDAR